NCT04938180View on ClinicalTrials.gov

A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 16, 2021

Primary Completion Date

April 20, 2022

Study Completion Date

May 17, 2022

Conditions
Tenosynovial Giant Cell TumorPigmented Villonodular SynovitisTGCTPVNS - Pigmented Villonodular Synovitis
Interventions
BIOLOGICAL

AMB-05X

AMB-05X is a fully human antibody antagonist (immunoglobulin G, type 2 \[IgG2\]) specific to the extracellular domain of human CSF1R

Trial Locations (5)

Unknown

AmMax Bio Clinical Site, Budapest

AmMax Bio Clinical Site, Warsaw

AmMax Bio Clinical Site, Dnipro

AmMax Bio Clinical Site, Kharkiv

AmMax Bio Clinical Site, Kyiv

Sponsors

Lead Sponsor

AmMax Bio, Inc.
All Listed Sponsors
lead

AmMax Bio, Inc.

INDUSTRY

NCT04938180 - A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients | Biotech Hunter | Biotech Hunter